Summary of Early Menopause May Increase Risk of Alzheimer’s Disease:
A recent study by Massachusetts General Brigham researchers analyzes the risk of Alzheimer’s disease (AD) dementia in women about their age at menopause and hormone therapy (HT) use. The findings suggest that women who experience menopause earlier may be at an increased risk of AD dementia. Still, those who receive HT close to menopause onset do not display an increased risk. The study also suggests that prolonged delay in HT initiation after menopause onset may increase the risk of tau deposition, a protein involved in AD dementia. The research highlights the importance of timely initiation of HT and may inform clinical guidelines for women’s health.
*****
Understanding the Connection Between Alzheimer’s Disease Risk, Age at Menopause, and Hormone Therapy
Introduction:
Alzheimer’s disease is a progressive brain disorder that causes problems with memory, thinking, and behavior. It is the most common cause of dementia in older adults, and women risk developing this disease more than men. Researchers from Mass General Brigham conducted a study to explore the link between Alzheimer’s disease risk, age at menopause, and hormone therapy. Their findings suggest that an early onset of menopause may increase the risk of developing Alzheimer’s disease dementia. However, hormone therapy started close to the beginning of menopause does not show any elevated risk.
Why Women are at Higher Risk Than Men for Alzheimer’s Disease:
Statistics indicate that women have a two-fold higher risk of developing Alzheimer’s disease than men. Women constitute two-thirds of individuals affected by Alzheimer’s disease in the United States. Research by the Mass General Brigham suggests that the risk of developing Alzheimer’s disease dementia may be linked to an early onset of menopause in women.
The Importance of Hormone Therapy:
Hormone therapy is a treatment option that can help women with menopause symptoms such as hot flashes, mood swings, and night sweats. Researchers from Mass General Brigham have found that hormone therapy starting soon after the onset of menopause can be safe and effectively reduce the risk of developing Alzheimer’s disease. However, the relationship between hormone therapy use and Alzheimer’s disease has been uncertain. Two decades ago, a study found that hormone therapy use was associated with a higher incidence of dementia than a placebo.
The Role of Beta-Amyloid and Tau in Alzheimer’s Disease:
Beta-amyloid and tau are two proteins that accumulate in the brain of Alzheimer’s disease patients. Beta-amyloid forms plaques, while tau forms tangles, leading to the death of nerve cells and the subsequent deterioration of brain function. Studies have shown that beta-amyloid and tau can be detected in the brains of individuals with Alzheimer’s disease years before symptoms appear.
How Hormone Therapy Can Affect Alzheimer’s Disease Risk:
Premature menopause, defined as menopause that occurs naturally before age 40 or due to surgical intervention before age 45, has been associated with an increased risk of Alzheimer’s disease dementia. Hormone therapy usage around menopause onset has been hypothesized to prevent cognitive impairment. The researchers found that hormone therapy used around menopause onset can reduce the risk of developing Alzheimer’s disease. However, hormone therapy initiated five years or more after menopause onset was associated with increased tau levels.
Conclusion:
Alzheimer’s is a severe brain disorder affecting memory, thinking, and behavior. Women have a higher risk of developing Alzheimer’s disease than men. Researchers from Mass General Brigham have found that an early onset of menopause in women can increase the risk of developing Alzheimer’s disease. However, hormone therapy used close to the start of menopause can reduce the risk of Alzheimer’s disease. However, delaying hormone therapy use after menopause onset leads to increased tau protein levels. This study highlights the importance of hormone therapy initiation timing in reducing the risk of Alzheimer’s disease in women.
Comments are closed